These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30264475)

  • 1. The effects of cancer-associated fibroblasts obtained from atypical ductal hyperplasia on anti-tumor immune responses.
    Gok Yavuz B; Gunaydin G; Kosemehmetoglu K; Karakoc D; Ozgur F; Guc D
    Breast J; 2018 Nov; 24(6):1099-1101. PubMed ID: 30264475
    [No Abstract]   [Full Text] [Related]  

  • 2. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.
    Nocera NF; Lee MC; Czerniecki BJ
    Future Oncol; 2017 Jul; 13(17):1459-1462. PubMed ID: 28766964
    [No Abstract]   [Full Text] [Related]  

  • 3. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
    Fracol M; Datta J; Lowenfeld L; Xu S; Zhang PJ; Fisher CS; Czerniecki BJ
    Ann Surg Oncol; 2017 Feb; 24(2):407-417. PubMed ID: 27663569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast.
    Tamiolakisl D; Venizelos I; Lambropoulou M; Jivannakis T; Seliniotakis E; Tsikouras P; Limberis V; Tsalkidis A; Papadopoulos N
    Acta Medica (Hradec Kralove); 2004; 47(4):257-62. PubMed ID: 15844251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primed atypical ductal hyperplasia-associated fibroblasts promote cell growth and polarity changes of transformed epithelium-like breast cancer MCF-7 cells via miR-200b/c-IKKβ signaling.
    Sun Y; Yang D; Xi L; Chen Y; Fu L; Sun K; Yin J; Li X; Liu S; Qin Y; Liu M; Hou Y
    Cell Death Dis; 2018 Jan; 9(2):122. PubMed ID: 29374150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.
    Barth PJ; Ebrahimsade S; Ramaswamy A; Moll R
    Virchows Arch; 2002 Mar; 440(3):298-303. PubMed ID: 11889601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.
    Yazhou C; Wenlv S; Weidong Z; Licun W
    Tumour Biol; 2004; 25(5-6):290-5. PubMed ID: 15627894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ductal carcinoma of the breast. An analysis of proportions of intraductal and invasive components.
    Matsukuma A; Enjoji M; Toyoshima S
    Pathol Res Pract; 1991 Jan; 187(1):62-7. PubMed ID: 1851298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative ultrastructure of atypical ductal hyperplasia, intraductal carcinoma, and infiltrating ductal carcinoma of the breast.
    Goldenberg VE; Goldenberg NS; Sommers SC
    Cancer; 1969 Dec; 24(6):1152-69. PubMed ID: 4311114
    [No Abstract]   [Full Text] [Related]  

  • 10. Microinvasive carcinoma of the breast: a diagnosis in search of a definition.
    Schnitt SJ
    Adv Anat Pathol; 1998 Nov; 5(6):367-72. PubMed ID: 10095878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An immunohistological study of monoclonal antibody BG6 against human breast cancer].
    Zhang SL
    Zhonghua Bing Li Xue Za Zhi; 1989 Mar; 18(1):59-61. PubMed ID: 2550156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between histology, monoclonal antibody reactivity, and prognosis in breast cancer.
    Yuan D; Dawson PJ
    Hum Pathol; 1987 Nov; 18(11):1097-100. PubMed ID: 2824320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CEA, grade and stage in breast carcinoma. Immunohistochemical study of 40 cases].
    Sironi M; Cantaboni A
    Pathologica; 1984; 76(1044):427-36. PubMed ID: 6096797
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical ductal hyperplasia from stereotactic core biopsy of the breast.
    Montgomery S
    AJR Am J Roentgenol; 1996 May; 166(5):1230. PubMed ID: 8615279
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.
    Chin Y; Janseens J; Vandepitte J; Vandenbrande J; Opdebeek L; Raus J
    Anticancer Res; 1992; 12(5):1463-6. PubMed ID: 1332579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of fibroblast immunophenotype and their clinical significance in stromal remodeling of breast tumors].
    Hua X; Huang X; Liao Z; Xian Q; Yu L
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):834-8. PubMed ID: 25620480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer.
    Gruber I; Landenberger N; Staebler A; Hahn M; Wallwiener D; Fehm T
    Anticancer Res; 2013 May; 33(5):2233-8. PubMed ID: 23645781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.